European Society For Organ Transplantation’s (ESOT) Guidelines For Desensitization Management Of Highly Sensitized Kidney Transplant Patients Printed In Transplant Worldwide

  • European guidelines target the treating of highly sensitized kidney transplant patients (patients with human leukocyte antigen (HLA) antibodies)
  • The following tips give a new clinical practice tool for medical professionals to assist achieve the perfect outcomes for highly sensitized kidney patients
  • Hansa Biopharma sponsors desensitization workstream included in ESOT’s educational programs, with an educational grant

Hansa Biopharma, pioneer in enzyme technology for rare immunological conditions, today welcomes the publication in Transplant Worldwide, the state journal of ESOT, of ESOT’s guidelines for desensitization management of highly sensitized kidney transplant patients.1

These European guidelines for the treating of highly sensitized kidney transplant people are caused by a specialist working group, brought by Professor Nizam Mamode M.D. Professor of Transplant Surgery, formerly at Guys and St Thomas Hospital, London, and based on other leading experts within the transplantation field. Although kidney transplantation rates have elevated in lots of countries recently, highly sensitized patients typically spend considerably extended period awaiting a transplant or may never receive one. ESOT has built a history in creating extensive educational and training programs around the most novel and burning topics within the field, promoting alterations in European policy, and it is dedicated to improving transplant patient outcomes.

“The following tips represent the very first Worldwide consensus on the management path for highly sensitized patients and articulates the variability in definitions, approaches, outcomes along with the perceived success of HLA-related transplantations,” states Luciano Potena, President of ESOT. “The following tips are members of ESOT’s educational transplant learning journey (TLJ) 2. series and therefore are targeted at medical professionals who have to face someone with HLA antibodies or donor-specific antibodies (DSAs), to be able to provide methodically solid, consensus-based guidance documents on clinical practice to enhance care and get a effective transplant. We hope these guidelines might help improve use of lifesaving kidney transplants for highly sensitized patients.”

Highly sensitized patients can be defined as probably the most immunologically complex patients around the transplant waiting lists. Because of the growth and development of HLA antibodies (HLA sensitization), triggered by pregnancy, transfusions or previous transplants, these people are hard to complement a compatible deceased donor and, consequently, may finish up waiting indefinitely around the transplant list without use of a kidney transplantation.2

Since 2020, Hansa is a proud sponsor from the HLA desensitization workstream included in ESOT’s educational transplant learning journey (TLJ) 2. series, supplying an academic grant to facilitate greater awareness among physicians of best practice for the treatment of highly sensitized kidney patients.